Related Experiment Video

Updated: Jul 16, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Exploring the specificity of the PI3K family inhibitor LY294002

Severine I Gharbi1, Marketa J Zvelebil, Stephen J Shuttleworth

  • 1Ludwig Institute for Cancer Research, Proteomics Unit, Cruciform Building, Gower Street, London WCE1 6BT, UK.

The Biochemical Journal
|February 17, 2007
PubMed

Insights

The widely used PI3K inhibitor LY294002 targets novel proteins beyond PI3Ks. This study used a proteomic approach to identify these off-target interactions, revealing a broader specificity profile for this critical research compound.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Phosphatidylinositol 3-kinases (PI3Ks) are crucial regulators of cellular processes like survival and growth.
  • Dysregulation of PI3K signaling is implicated in cancer and inflammatory diseases.
  • Commonly used PI3K inhibitors, such as LY294002, may lack specificity, affecting other kinases and proteins.

Purpose of the Study:

  • To investigate the precise target specificity of the PI3K inhibitor LY294002.
  • To identify novel protein targets interacting with LY294002 using a chemical proteomic strategy.

Main Methods:

  • An analogue of LY294002, PI828, was immobilized on epoxy-activated Sepharose beads to create an affinity bait.
  • Cellular extracts were incubated with the immobilized PI828 to capture binding proteins.
  • High-affinity proteins were separated by gel electrophoresis and identified using liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Main Results:

  • The study identified that LY294002 binds not only to class I PI3Ks and PI3K-related kinases but also to previously unrecognized protein targets.
  • These novel targets appear unrelated to the PI3K signaling family, indicating broader off-target effects.
  • The proteomic approach successfully fished out proteins with high affinity for the immobilized LY294002 analogue.

Conclusions:

  • The PI3K inhibitor LY294002 exhibits a wider range of protein interactions than previously understood.
  • These findings highlight the importance of assessing inhibitor specificity to accurately interpret experimental results in PI3K research.
  • The identified novel targets warrant further investigation for their potential roles in cellular signaling and disease.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...